Tiziano Barbui

TL;DR: Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.

TL;DR: The binding of affinity-purified anticardiolipin antibodies (ACA) to liposomes that contained cardiolip in or phosphatidylserine was investigated and aca-cofactor, a single chain polypeptide with an apparent molecular weight of 50 kD (non-reduced), increases to 70 kD upon reduction, and its properties closely resemble those of beta 2-glycoprotein I (apolipoprotein H).

TL;DR: The detection of lupus anticoagulants and, possibly, of immunoglobulin G (IgG) anticardiolipin antibodies at medium or high titers helps to identify patients at risk for thrombosis, however, to take full advantage of the conclusions provided by the available evidence, there is an urgent need to harmonize investigational methods.

TL;DR: In this paper, the authors proposed a revision of the current World Health Organization (WHO) diagnostic criteria for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), which was subsequently presented by an international expert panel of pathologists and clinical investigators in myeloproliferative disorders.

TL;DR: Low-dose aspirin can safely prevent thrombotic complications in patients with polycythemia vera who have no contraindications to such treatment, and reduced the risk of the combined end point of nonf fatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thromBosis, or death from cardiovascular causes.